The health care sector is likely reacting to the uncertainty created by the effect of cuts to the federal budget now being ...
Morgan Stanley raised the firm’s price target on Moderna (MRNA) to $39 from $38 and keeps an Equal Weight rating on the shares. The company’s ...
Bernstein analyst Courtney Breen maintained a Hold rating on Moderna (MRNA – Research Report) on February 14 and set a price target of $45.00.
Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, ...
Kengo Kuma and Associates’ extension to Lisbon’s Centro de Arte Moderna is a gesture that bears no relation to the existing ...
The U.S. FDA has paused Moderna's norovirus vaccine trial due to a neurological side effect. Meanwhile, Robert F. Kennedy Jr.
Wilmington Savings Fund Society FSB grew its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 295.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 786 shares of the ...
Moderna Inc.’s stock erased early losses to gain more than 3% on Friday, after the biotech company posted a ...
National Transportation Safety Board (NTSB) chair Jennifer Homendy provides an update Friday into the investigation of the ...
Super Micro Computer rises sharply, Nvidia sells its stake in SoundHound, Airbnb swings to a profit in the fourth quarter, and Moderna posts a wider-than-expected quarterly loss.
The biotech giant reported a bigger-than-expected quarterly loss. Finance chief James Mock attributed the loss to a scale down.
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results